Implanet SA AI Stock Analysis
Want to see FR:ALIMP full AI Analyst Report?
Implanet SA (ALIMP) AI Stock Analysis
Implanet SA
(Paris:ALIMP)
The overall score is heavily pressured by a fragile financial position, including high leverage and unprofitability, despite strong top-line growth. Technical trends are bearish, and the negative P/E ratio underscores a lack of earnings power. The company shows operational improvement but remains a high-risk investment.
Implanet SA (ALIMP) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 20.74M
- Dividend Yield
- ―
- Average Volume (3M)
- 58.51K
- Price to Earnings (P/E)
- -5.0
- Beta (1Y)
- -0.02
- Revenue Growth
- 24.35%
- EPS Growth
- 15.00%
- Country
- France
- Employees
- 49
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Implanet SA Business Overview & Revenue Model
Company Description
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its s...
How the Company Makes Money
Implanet generates revenue primarily from selling orthopedic and spine implant products and the associated surgical instruments/ancillaries required to perform procedures using its systems. Revenue is typically recognized through product sales to hos...
Implanet SA Financial Statement Overview
Summary
Strong revenue growth and improving gross margins are offset by persistent net losses, negative cash flow, and a highly leveraged balance sheet with minimal equity. The financial profile remains high-risk despite operational progress.
Income Statement
25NegativeBalance Sheet
12Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.80M | 12.47M | 9.41M | 7.45M | 8.03M | 6.14M |
| Gross Profit | 8.08M | 5.93M | 4.10M | 3.13M | 3.91M | 2.74M |
| EBITDA | -3.78M | -2.91M | -3.82M | -5.08M | -1.84M | -2.70M |
| Net Income | -4.42M | -4.38M | -4.37M | -6.68M | -3.54M | -4.61M |
Balance Sheet | ||||||
| Total Assets | 17.74M | 18.45M | 14.89M | 10.64M | 14.47M | 16.70M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01M | 3.01M | 1.60M | 248.00K | 531.00K | 1.87M |
| Total Debt | 5.46M | 5.92M | 6.50M | 6.15M | 6.80M | 9.61M |
| Total Liabilities | 19.46M | 18.04M | 14.16M | 10.81M | 10.93M | 13.90M |
| Stockholders Equity | -1.72M | 404.00K | 727.00K | -174.00K | 3.54M | 2.80M |
Cash Flow | ||||||
| Free Cash Flow | -2.29M | -2.15M | -2.81M | -2.17M | -3.04M | -3.91M |
| Operating Cash Flow | -733.00K | -589.00K | -2.32M | -1.45M | -2.47M | -3.52M |
| Investing Cash Flow | -1.62M | -1.56M | -844.00K | -768.00K | -570.00K | 1.57M |
| Financing Cash Flow | 2.96M | 3.64M | 4.37M | 1.95M | 1.60M | 2.73M |
Implanet SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALIMP, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.16, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.84 is Neutral, neither overbought nor oversold. The STOCH value of 70.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALIMP.
Implanet SA Peers Comparison
Overall Rating
FR:CVX49Neutral
FR:ALTHE46Neutral
FR:ALMKT45Neutral
FR:ALMDT43Neutral
FR:ALIMP41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | EUR 298.69M | -7.38 | -120.57% | ― | -100.00% | -72.33% | |
| 46Neutral | EUR 42.79M | -5.60 | 453.10% | ― | -16.98% | 20.31% | |
| 45Neutral | EUR 17.81M | 1.44 | -157.72% | ― | 3.38% | ― | |
| 43Neutral | EUR 209.76M | -3.48 | 271.64% | ― | 2.16% | -5.26% | |
| 41Neutral | EUR 20.74M | -5.02 | 671.47% | ― | 24.35% | 15.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALIMP | Implanet SA | 0.14 | -0.05 | -25.77% | |
| FR:ALMKT | MAUNA KEA TECHNOLOGIES | 0.09 | 0.01 | 10.98% | |
| FR:ALTHE | Theraclion SA | 0.58 | -0.09 | -13.95% | |
| FR:ALDMS | Diagnostic Medical Systems | 0.91 | -0.36 | -28.19% | |
| FR:ALMDT | Median Technologies | 4.28 | 1.35 | 45.83% | |
| FR:CVX | Affluent Medical SA | 4.80 | 3.23 | 206.71% |
Implanet SA Corporate Events
Implanet extends growth streak on spine implants and U.S. surge
Implanet reported its ninth consecutive quarter of growth, with third-quarter 2026 revenue up 18% to €3.44 million and nine‑month revenue rising 21% to €10.57 million, driven by strong demand for spine implants and SMTP medical equipment. The United...
Implanet lifts H1 revenue 23% as Jazz Spinal System drives margin gains
Implanet reported first-half 2026 revenue of €7.1 million, up 23% year-on-year, with growth driven by its spine implants business and the strong performance of the new Jazz Spinal System hybrid posterior fixation solution. Sales of the SMTP ultrasoni...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026
